fregime
TODAYSTOCKSARCHIVEABOUTGUIDE
Sign inFollow your stocks

Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 30 Sep 2026

ZYDUSLIFE, full dossier

Zydus Lifesciences stock hit a fresh 52-week high of ₹ 1,232.10 on Tuesday, even as the broader market remained under pressure.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

Zydus Lifesciences stock hit a fresh 52-week high of ₹ 1,232.10 on Tuesday, even as the broader market remained under pressure.

livemint.com29 Sep 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Zydus Lifesciences

₹1,145.70

▼ -1.40%

Close (EOD), as of 1 Oct 2026 · source

Zydus Lifesciences: results, dividends, orders, the full cited record →

More on Zydus Lifesciences

US pharma tariff relief has different implications for Indian drugmakers depending on whether their US business is built around patented medicines, generics, complex injectables or contract manufacturing.

2 Oct 2026 · 1 publisher

Zydus Lifesciences said the USFDA concluded its inspection of the company’s SEZ II manufacturing facility in Ahmedabad with one observation and no data integrity-related observations.

30 Sep 2026 · 4 publishers

Mapro Foods is evaluating options to bring in a strategic partner, with Zydus Wellness, Blackstone, and Apax Partners showing initial interest.

29 Sep 2026 · 1 publisher

Dr Reddys Laboratories Ltd is quoting at Rs 1213, up 0.17% on the day as on 12:44 IST on the NSE.

24 Sep 2026 · 2 publishers

Zydus Lifesciences expects decent growth for the next five years as its innovation matures.

24 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.